Development of a New Approach for the Therapy of Prostate Cancer with SPOP MutationsReportar como inadecuado




Development of a New Approach for the Therapy of Prostate Cancer with SPOP Mutations - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advanced prostate cancer is treated with androgen deprivation, but mostpatients eventually progress and need new therapy. Recent genomic-exomicsequencing identified SPOP as the most frequently mutated gene in 6% - 15% ofprostate cancer. Based on the function of SPOP as a ubiquitin ligase in proteindegradation, it was hypothesized that loss-of-function mutations of SPOP led toaccumulation of SPOP substrates that enhance androgen receptor activity andfacilitate prostate cancer formation. SPOPsubstrates could thus be potential targets for treatment of androgen-sensitiveprostate cancer. PubMed and BLAST search identified that Gli, SRC-3, and AWP1are SPOP substrates, and that inhibition of PRK-1, a binding partner of AWP1,by lestaurtinib suppressed androgen receptor activity. LNCaP, PC3, DU145 and22RV1 prostate cancer cells were used to evaluate the effect of lestaurtinib.LNCaP cells, an androgen-sensitive prostate cancer cell line, were the mostsensitive. SRC-3 protein decreased when LNCaP cells were treated withlestaurtinib; whereas PRK-1 increased in nucleus after lestaurtinib treatment.These data suggest that lestaurtinib modulates SRC-3 and PRK-1 toinduced cell death in androgen-sensitive prostate cancer, and could be a usefulagent for future development for prostate cancer with SPOP mutations.

KEYWORDS

Prostate Cancer, SPOP, SRC-3, PRK-1, Lestaurtinib

Cite this paper

Lu, D. , Lee, J. , Lee, A. and Lee, R. 2015 Development of a New Approach for the Therapy of Prostate Cancer with SPOP Mutations. Journal of Cancer Therapy, 6, 841-848. doi: 10.4236-jct.2015.610092.





Autor: David Lu, Jason J. Lee, Allen J. Lee, Ray M. Lee*

Fuente: http://www.scirp.org/



DESCARGAR PDF




Documentos relacionados